Academisch Ziekenhuis Maastricht

7 trials 3 recruiting Academic / non-commercial

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

3 Recruiting

0 Completed trials

1 Countries active

13 Unique IMPs

N/A Results reported

Phase II

Phase III/IV

Phase IV

Phase I (FiH)

Phase II: 4 Phase III/IV: 1 Phase IV: 1 Phase I (FiH): 1

Top indications

Lung neoplasm malignant 2 Small cell lung cancer metastatic 1 Mitochondrial myopathy 1

Top IMPs

(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 1 AUTOLOGOUS MUSCLE PRECURSOR CELLS 1 BEVACIZUMAB 1 FEBUXOSTAT 1 FLUDEOXYGLUCOSE (18F) 1 OSIMERTINIB 1 SACITUZUMAB GOVITECAN 1 TARLATAMAB 1

All trials

7 total

Assess effect and safety of intra-arterial autologous mesoangioblast administration to the upper arm of m.3243A>G mutation carriers Pending

2024-515129-27-00 Phase I (FiH) 1 country AUTOLOGOUS MUSCLE PRECURSOR CELLS
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small … Pending

2025-522162-75-00 Phase II 1 country TARLATAMAB
Improved baseline staging with 68Ga-FAPI-46 PET in non-small cell lung cancer – a pilot study Pending

2025-523032-39-00 Phase II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
Boosting osimertinib Blood Brain Barrier penetration in patients with epidermal growth factor receptor mutated non-small cell lung cancer (O… Pending

2025-523033-26-00 Phase II 1 country FEBUXOSTAT; OSIMERTINIB
Assessing the Efficacy of a Single Measurement and Adjustment Strategy for DOACs in Frail Older Patients. Recruiting

2025-521362-10-00 Phase III/IV 1 country
Sacituzumab govitecan (SG) with bevacizumab for the treatment of brain metastases from non-small cell lung cancer (NSCLC) Recruiting

2024-514066-40-00 Phase II 1 country BEVACIZUMAB; SACITUZUMAB GOVITECAN
The effect of perioperative intravenous s-ketamine on acute and chronic postoperative craniotomy pain compared to placebo Recruiting

2024-514020-16-00 Phase IV 1 country

Showing 1–7 of 7 trials

← All sponsors A–Z